PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026Clinical Case Reports2 citationsOpen Access

Thrombotic Thrombocytopenic Purpura in a Patient With Triple‐Negative Breast Cancer Treated With PD ‐ L1 Inhibition and Taxane Chemotherapy

View Full Paper
JKJason KeACAlbert C. ChongRHRobert Y. Hsu

Key Points

  • To explore the occurrence of thrombotic thrombocytopenic purpura associated with PD-L1 therapy in breast cancer.
  • Case report of a patient with triple-negative breast cancer
  • Evaluation of symptoms including anemia and thrombocytopenia
  • Assessment of the relationship between PD-L1 inhibitors and TTP
  • Patient developed thrombotic thrombocytopenic purpura while on PD-L1 and taxane treatment
  • Symptoms included new or worsening anemia and thrombocytopenia
  • Workup indicated presence of thrombotic microangiopathy

Abstract

ABSTRACT Thrombocytopenic purpura (TTP) is a hematologic emergency that may occur with PD‐L1 immunotherapy. New or worsening anemia and thrombocytopenia in patients started on PD‐L1 inhibitors should raise suspicion for TTP and prompt workup for thrombotic microangiopathy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ke et al. (2026) studied this question.

synapsesocial.com/papers/69b4add218185d8a39801e2dhttps://doi.org/10.1002/ccr3.72247
Ask AI
Helpful
Bookmark
Share
View Full Paper